Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials

C. Palmer, Suetonia; Tendal, Britta; A. Mustafa, Reem; Olav Vandvik, Per; Li, Sheyu; Hao, Qiukui; J. Tunnicliffe, David; Ruospo, Marinella; Natale, Patrizia; Saglimbene, Valeria; Nicolucci, Antonio; W. Johnson, David; Tonelli, Marcello; Chiara Rossi, Maria; V. Badve, Sunil; Cho, Yeoungjee; Nadeau‐Fredette, Annie‐Claire; Burke, Michael; Imran Faruque, Labib; Lloyd, Anita; Ahmad, Nasreen; Liu, Yuanchen; Tiv, Sophanny; Millard, Tanya; Gagliardi, Lucia; Kolanu, Nithin; Barmanray, Rahul; McMorrow, Rita; Karina Raygoza Cortez, Ana; White, Heath; Chen, Xiangyang; Zhou, Xu; Liu, Jiali; Flores Rodríguez, Andrea; Díaz González-Colmenero, Alejandro; Wang, Yang; Li, Ling; Sutanto, Surya; César Solís, Ricardo; Díaz González-Colmenero, Fernando; Rodríguez‐Gutiérrez, René; Walsh, Michael; Guyatt, Gordon; FM Strippoli, Giovanni

doi:10.1136/bmj.m4573

Public

Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials

Published in BMJ • Jan 13, 2021

Authors:

Suetonia C. Palmer

Britta Tendal

Reem A. Mustafa

Abstract

OBJECTIVE: To evaluate sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists in patients with type 2 diabetes at varying cardiovascular and renal risk. DESIGN: Network meta-analysis. DATA SOURCES: Medline, Embase, and Cochrane CENTRAL up to 11 Augus...

Subject

Medicine

Type 2 diabetes

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!